Nicox S.A. (NICXF)
- Previous Close
0.4400 - Open
0.4400 - Bid --
- Ask --
- Day's Range
0.4400 - 0.4400 - 52 Week Range
0.4400 - 0.6400 - Volume
100 - Avg. Volume
0 - Market Cap (intraday)
22.132M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.
www.nicox.comRecent News: NICXF
Performance Overview: NICXF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NICXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NICXF
Valuation Measures
Market Cap
20.18M
Enterprise Value
22.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.57
Price/Book (mrq)
0.45
Enterprise Value/Revenue
3.95
Enterprise Value/EBITDA
-1.42
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-13.26%
Return on Equity (ttm)
-32.68%
Revenue (ttm)
3.57M
Net Income Avi to Common (ttm)
-17.36M
Diluted EPS (ttm)
-0.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
19.01M
Total Debt/Equity (mrq)
46.46%
Levered Free Cash Flow (ttm)
-13.31M
Research Analysis: NICXF
Company Insights: NICXF
NICXF does not have Company Insights